Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 .
VALNEVAApril 20, 2021 GMT
Saint-Herblain (France), April 20, 2021 – ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).
This follows the recent announcement on April 6, 2021 of positive initial results from the Phase 1/2 clinical trial of VLA20011.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and .
VALNEVAApril 12, 2021 GMT
Saint-Herblain (France), April 12, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV) 1.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates
VALNEVAApril 10, 2021 GMT
Saint-Herblain (France), April 10, 2021 – Valneva SE (“Valneva” or the “Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announces today the publication of its 2020 Universal Registration Document filed with the French Financial Markets Authority on April 9, 2021 under the filing number D.21-0286.
Valneva’s 2020 Universal Registration Document notably includes the Company’s 2020 Annual Financial Report, Management Board Report, the Supervisory Board’s report on Corporate Governance including information on the conditions of preparation and organization of the Supervisory Board’s work and on the internal control and risk
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Files Registration Statement for Proposed United States Initial Public Offering
VALNEVAApril 10, 2021 GMT
Saint-Herblain (France), April 10, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”), representing ordinary shares, in the United States, and a concurrent offering of its ordinary shares in certain jurisdictions outside of the United States (together, the “Global Offering”). All securities to be sold in the Global Offering will be offered by the Company. The number of ordinary shares to be repre